Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1082-1088

  Daemen, Toos ^a   Riezebos Brilman, Annelies ^a   Bungener, Laura ^a   Regts, Joke ^a   Dontje, Bert ^a   Wilschut, Jan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

CTL; Human papillomavirus; Semliki Forest virus

Indexed keywords

CANCER VACCINE; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; TUMOR; TUMOR REGRESSION; VIRUS CAPSID; VIRUS CELL TRANSFORMATION; VIRUS RECOMBINANT; WART VIRUS;

ANIMALS; CELL LINE; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOLOGIC MEMORY; MESOCRICETUS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SEMLIKI FOREST VIRUS; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0037424127     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00558-3     Document Type: Article

References (35)

1. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer. 37:2001;S4-S66.
2. Ferenczy A., Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3:2002;11-16.
3. Broker T.R., Jin G., Croom-Rivers A.et al. Viral latency - the papillomavirus model. Dev. Biol. (Basel). 106:2001;443-451.
4. Bontkes H.J., de Gruijl T.D., van den Muysenberg A.J.et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int. J. Cancer. 88:2000;92-98.
5. Schirmbeck R., Reimann J. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Biol. Chem. 382:2001;543-552.
6. Mendez S., Gurunathan S., Kamhawi S.et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:2001;5122-5128.
7. Bonnet M.C., Tartaglia J., Verdier F.et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74:2000;11-25.
8. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (New York). 9:1991;1356-1361.
9. Daemen T., Pries F., Bungener L., Kraak M., Regts J., Wilschut J. Genetic immunisation against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 7:2000;1859-1866.
10. Daemen T., Regts J., Holtrop M., Wilschut J. Immunisation strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 9:2002;85-94.
11. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W.et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
12. Van der Burg S.H., Kwappenberg K.M., O'Neill T.et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 19:2001;3652-3660.
13. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F.et al. Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen. Cancer Res. 56:1996;21-26.
14. Smits P.H.M., Smits H.L., Jebbink M.F., Ter Schegget J. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA. Virol. 176:1990;158-165.
15. De Bruijn M.L., Schuurhuis D.H., Vierboom P.et al. Immunisation with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC Class I-restricted protection to HPV16-induced tumour cells. Cancer Res. 58:1998;724-731.
16. Ossevoort M.A., Feltkamp M.C., van Veen K.J., Melief C.J., Kast W.M. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced. J. Immunother. Emphasis Tumour Immunol. 18:1995;86-94.
17. He Z., Wlazlo A.P., Kowalczyk D.W.et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 270:2000;146-161.
18. Osen W., Peiler T., Ohlschlager P.et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine. 19:2001;4276-4286.
19. Liu D.W., Tsao Y.P., Kung J.T.et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74:2000;2888-2894.
20. Chu N.R., Wu H.B., Wu T-C., Boux L.J., Siegel M.I., Mizzen L.A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121:2000;216-225.
21. Gunn G.R., Zubair A., Peters C., Pan Z.K., Wu T.C., Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumours immortalized by HPV-16. J. Immunol. 167:2001;6471-6479.
22. Lamikanra A., Pan Z.K., Isaacs S.N., Wu T.C., Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumours in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumour site. J. Virol. 75:2001;9654-9664.
23. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R.et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:2002;350-358.
24. Velders M.P., McElhiney S., Cassetti M.C.et al. Eradication of established tumours by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61:2001;7861-7867.
25. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., Liljestrom P. Outcome of immunisation of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses. 13:1997;1487-1495.
26. Mossman S.P., Bex F., Berglund P.et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70:1996;1953-1960.
27. Notka F., Stahl-Hennig C., Dittmer U., Wolf H., Wagner R. Construction and characterization of recombinant VLPs and Semliki Forest virus live vectors for comparative evaluation in the SHIV monkey model. Biol. Chem. 380:1999;341-352.
28. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 251:1998;28-37.
29. Cheng W.F., Hung C.H., Chai C.Y.et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 75:2001;2368-2376.
30. Glasgow G.M., McGee M.M., Tarbatt C.J., Mooney D.A., Sheahan B.J., Atkins G.J. The Semliki Forest virus vector induces p53-independent apoptosis. J. Gen. Virol. 79:1998;2405-2410.
31. Restifo N.P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adoptive immunity. Curr. Opin. Immunol. 12:2000;597-603.
32. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74:2000;914-922.
33. Hu H.M., Winter H., Urba W.J., Fox B.A. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 165:2000;4246-4253.
34. Surman D.R., Dudley M.E., Overwijk W.W., Restifo N.P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumour antigen. J. Immunol. 164:2000;562-565.
35. Marzo A.L., Kinnear B.F., Lake R.A.et al. Tumour-specific CD4+ T cells have a major "post-licencing" role in CTL mediated anti-tumour immunity. J. Immunol. 165:2000;6047-6055.